Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of

Francesco Costa1, Claudio Montalto2, Mattia Branca3

  • 1Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, A.O.U. Policlinic 'G. Martino', Messina 98100, Italy.

European Heart Journal
|December 8, 2022
PubMed

Insights

Shorter dual antiplatelet therapy (DAPT) durations of 1 or 3 months significantly reduce bleeding and cardiovascular mortality in high bleeding risk patients after percutaneous coronary intervention. These abbreviated regimens do not increase ischemic event risk compared to standard longer durations.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Optimal duration of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) for high bleeding risk (HBR) patients remains uncertain.
  • Existing evidence is synthesized to evaluate abbreviated DAPT regimens in HBR populations.

Approach:

  • A systematic review and meta-analysis of randomized clinical trials was conducted.
  • Included trials compared abbreviated (1 or 3 months) DAPT with standard (≥6 months) DAPT in HBR patients without need for oral anticoagulation.
  • Data from 11 trials involving 9006 patients were analyzed.

Key Points:

  • Abbreviated DAPT significantly reduced major or clinically relevant non-major bleeding (RR: 0.76) and major bleeding (RR: 0.80).
  • Cardiovascular mortality was also lower with abbreviated DAPT (RR: 0.79).
  • No significant differences were observed in all-cause mortality, major adverse cardiovascular events, myocardial infarction, or stent thrombosis.

Conclusions:

  • In HBR patients undergoing PCI, 1- or 3-month DAPT regimens are associated with reduced bleeding and cardiovascular mortality.
  • These shorter DAPT durations do not appear to increase ischemic event risk compared to standard ≥6-month regimens.
  • Findings were consistent across different HBR definitions and clinical presentations.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
585
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
21
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
24
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
16